2617.HK stock surged 56.60% to HKD 92.00 at the HKSE close on 06 Mar 2026, making TransThera one of today’s top gainers in Hong Kong. The move came on 31,145,975 shares, almost five times the average volume, and pushed the day high to HKD 93.30 from an open of HKD 64.45. Traders cited heavy volume and inclusion in biotech coverage as key drivers. We review price action, technicals, valuation and Meyka AI forecasts to frame near-term trade ideas and risks.

Price action and drivers: 2617.HK stock surge

TransThera (2617.HK) closed at HKD 92.00, up 56.60% from the previous close of HKD 58.75 on 06 Mar 2026. Volume hit 31,145,975 versus an average of 1,260,297, giving a relative volume of 4.92x and signalling outsized participation. Market commentary points to ETF and sector flows and heavy intraday buying as catalysts; the stock also traded to a day high of HKD 93.30. See ETF holdings for sector context Global X China Biotech ETF holdings.

Technical read and momentum

Momentum indicators show mixed signals after the jump. RSI sits at 34.03, MACD histogram is 1.23, and ADX reads 30.60, indicating a strong trend but limited upside momentum by RSI. The 50-day average is HKD 87.29 and the 200-day average is HKD 110.20, so the move cleared near-term resistance but the 200-day average remains overhead. Traders should watch intraday volatility, ATR 6.12, and the Bollinger middle at HKD 68.37 for support and resistance cues.

Meyka AI rates 2617.HK with a score out of 100

Meyka AI rates 2617.HK with a score of 66.58 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights balanced upside potential against stretched valuation and clinical-stage execution risk. Grades are model outputs for information only and are not investment advice.

Valuation, fundamentals and risks

2617.HK stock shows clinical-stage biotech fundamentals with negative earnings and high volatility. Reported EPS is -0.68 and PE is -94.26, reflecting losses and early commercialisation risk. Market cap stands near HKD 25,444,147,386.00 with 396,944,577.00 shares outstanding. The year high is HKD 679.50 and year low HKD 20.20, underscoring wide price swings. Key risks include trial outcomes, cash burn, and thin coverage; liquidity spikes can amplify moves.

Meyka AI’s forecast model projects price levels and upside

Meyka AI’s forecast model projects a monthly level of HKD 111.78, a quarterly level of HKD 145.57, and a yearly level of HKD 221.50. Versus the current HKD 92.00, these imply short-term upside of 21.50%, medium-term upside of 58.20%, and 12-month upside of 140.71%. Forecasts are model-based projections and not guarantees; they should be weighed with clinical milestones and cash runway.

Trading takeaways and strategy

Short-term traders may target HKD 110.00 as an initial upside level and use intraday support near HKD 63.00 and the prior close HKD 58.75 for stop placement. A 12-month price target aligned with Meyka’s model is HKD 221.50, while conservative holders should watch dilution risk and clinical readouts. TransThera trades on the HKSE in Hong Kong and fits a high-beta, biotech allocation with tight risk controls.

Final Thoughts

TransThera (Nanjing) Inc., trading as 2617.HK stock on the HKSE, delivered a sharp 56.60% gain to HKD 92.00 on 06 Mar 2026 on very heavy volume, making it a clear top gainer in Hong Kong biotech today. Technical indicators show a strong trend but mixed momentum, and valuation remains challenged with EPS -0.68 and PE -94.26. Meyka AI’s forecast model projects a yearly level of HKD 221.50, implying 140.71% upside from today’s close; this is a model projection, not a guarantee. Traders should balance the forecast against clinical and financing risk, use disciplined stops, and consider position sizing consistent with a biotech allocation. Our coverage draws on Meyka AI’s grade and model output to frame risk-adjusted opportunity in a volatile sector

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.